Результаты поиска

Reversible metastatic pulmonary calcification in a patient with multiple myeloma.

A-52-year-old patient presented with a 2-year history of multiple myeloma, recurrent episodes of hypercalcemia, and extensive bone involvement. She developed pulmonary infiltrates, initially misdiagnosed as interstitial pneumonia. High-resolution computed tomography and bone scintiscanning indicated pulmonary calcification, which was confirmed by a transbronchial biopsy. Cytostatic treatment of multiple myeloma in combination with repetitive i.v. administration of bisphosphonates over a period of 6 months led to a significant improvement of clinical symptoms. Regression of pulmonary infiltrate

Isolated hyperthermic limb perfusion chemotherapy in Merkel cell tumour: a case report.

Merkel cell carcinoma of the skin is a rare malignant tumour first described in 1972 by Toker. The optimal management of this disease has not been clearly defined, especially that of advanced locoregional disease. Surgery, radiotherapy and chemotherapy have been advocated separately or in combination, with less-than-optimal results. Localized high-dose chemotherapy has never been tried, although it would seem to be the logical step forward.

The prognostic significance of X-ray changes at presentation and reassessment in patients with multiple myeloma.

The relationship between presenting skeletal X-ray findings and survival in multiple myeloma was assessed in 172 consecutive patients treated at this institute. All patients were investigated, treated and followed up according to one protocol. The shortest survival was seen in those with normal X-rays (3-year actuarial 11 per cent) and the longest in those with minimal lytic changes (3-year actuarial 44 per cent). Patients with osteoporosis alone and those with extensive lytic lesions had intermediate survivals of 32 per cent and 33 per cent respectively. Of the other major prognostic features

Hyperthermic regional perfusion in high-risk stage-I malignant melanomas of the extremities.

Local recurrence after conventional surgical treatment of malignant melanomas of the extremities has frequently been observed in our department in the past. As at other centers, this sometimes necessitated amputation, and on a few occasions amputations were performed exclusively for palliative reasons. In an effort to improve this situation, regional perfusion as local regional treatment was added to conventional therapy in 1965. We have since observed no further instances of massive local tumor growth, and since that time no amputations have had to be performed for this reason. Of course this

Osteosclerotic myeloma and peripheral neuropathy.

Sixteen cases of osteosclerotic myeloma and peripheral neuropathy (SM-PN) were reviewed. The neuropathy resembled chronic inflammatory-demyelinating polyneuropathy with predominantly motor disability, high CSF protein levels, and low motor nerve conduction velocities. Twelve of the 16 patients had detectable levels of monoclonal serum proteins, all with lambda light chains, but results of other laboratory studies were usually normal. Most of the patients also had organomegaly, endocrine abnormalities, or both. Treatment of solitary lesions with tumoricidal irradiation usually improved the neur

[Clinical experience in the diagnosis and therapy of plasmacytoma (author's transl)].

8 patients with plasmocytomas were treated with Endoxan and compared with 5 patients without any considerable treatment. Diagnosis, therapy and prognosis of plasmocytoma are discussed. Particularly mentioned are 3 patients with secondary tumours during cytostatic treatment, a plasmocytoma without paraprotein, a tumorous plasmocytoma with double paraproteinemia and a gammopathia with further development into a plasmocytoma 10 years later.

Novel Cinnamaldehyde Hydrazones: Design, In Silico Evaluation, Synthesis, and Cytotoxic Activity.

(1) Background: Cinnamaldehyde exhibits a broad spectrum of biological activities, and its α,β-unsaturated aldehyde scaffold serves as a ver … c activity against T-cell leukemia KE-37 cells (IC50 = 20.3 ± 2.8 μM), comparable to reference drug melphalan (IC50 = 21.40 ± 3.9 μM), and the highest selectivity index (≥19.7). Structure-activity analysis suggests that an amino substituent enhances both potency and selectivity. (4) Conclusions: Overall, these findings identify cinnamaldehyde hydrazones as …

- Имитационная оценка соответствия режима дозировки многочисленным миеломным лекарствам, отражающим демографические и этнические различия.

Из-за трудностей, связанных с проведением клинических испытаний в небольших и неоднородных группах населения, часто не проводятся исследования, посвященные таким болезням сирот, как множественная миелома (ММ). Вместе с тем демографические и региональные различия между участниками испытаний и азиатскими группами населения могут влиять на воздействие наркотиков и принимаемые меры реагирования. В этом исследовании была проведена оценка потенциальных различий в воздействии наркотиков и реакции на них между многонациональными клиническими пробными группами населения (ТП) и корейскими пациентами (КП

Совпадение в аннотации оригинала
Bridging studies are often waived for orphan diseases such as multiple myeloma (MM) due to challenges in conducting clinical trials in small … e ≥ 3 hematologic adverse events. No meaningful exposure differences were observed for daratumumab, melphalan, or panobinostat. These findings suggest that demographic and regional differences between TP and KP may translate into measurable differences in predicted drug exposure for selected multiple myeloma therapies. Simulation-based approaches integratin …

Transcriptomic profiling unveils novel therapeutic options for drug-resistant temporal lobe epilepsy.

BACKGROUND: Epilepsy drug treatments fail in 25-30 % of patients, leading to drug resistance. Temporal lobe epilepsy is the most prevalent s … these, we selected only the 11 which can cross the blood-brain barrier: cobimetinib, panobinostat, melphalan, rucaparib, alectinib, ponatinib, danazol, carboplatin, vandetanib, erlotinib, and gefitinib. After analyzing their mechanisms to modulate epileptogenesis, their safety and efficacy profiles from previous publications, we provide a list of the top 5 …

Safety and efficacy of G-CSF alone with pre-emptive plerixafor for autologous peripheral blood hematopoietic stem cell mobilization in newly diagnosed multiple myeloma.

BACKGROUND: Mobilization failure remains a challenge in autologous stem cell transplantation for multiple myeloma (MM). Chemotherapy-based m … s was 2 (range: 1-4). The median CD34 yield was 6.4 × 106 cells/kg. All patients received high-dose melphalan and underwent autologous transplant, with median neutrophil and platelet engraftment at 12 and 15 days, respectively. All patients were alive at day 100 post-transplant. CONCLUSION: An algorithm-driven, G-CSF-only mobilization with pre-emptive Pler …

"B" symptoms and CBV conditioning negatively impact survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation.

INTRODUCTION: Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma with limited curative options. Autologous stem cell tr … ently associated with inferior OS and PFS. In contrast, BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning was associated with improved outcomes. Treatment-related mortality at day 100 was 3.4%. Post-transplant complications occurred in 64% of patients, most commonly infections and mucositis. Rituximab maintenance was used in only 17% of ca …

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.

Primary mediastinal large B-cell lymphoma (PMBCL) is an uncommon, aggressive type of non-Hodgkin lymphoma. Rituximab-containing chemoimmunot … 22. The 60 study patients received either rituximab-BEAM (n = 37) or rituximab-gemcitabine/busulfan/melphalan (R-GemBuMel) with or without vorinostat (n = 23), followed by ASCT. Forty-six patients received mediastinal RT, either as prior consolidation of frontline therapy or following ASCT. At median follow-up of 6 years (range, .3 to 21 years), the 5-year …

Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.

INTRODUCTION: Two phase 3 studies demonstrated superior efficacy of intravenous daratumumab (DARA IV) plus bortezomib/melphalan/prednisone (ALCYONE) or lenalidomide/dexamethasone (Rd; MAIA) versus standard-of-care regimens for transplant-ineligible newly diagnosed multiple myeloma. In these studies, patients could switch from DARA IV to subcutaneous daratumumab (DARA SC) while receiving daratumumab monotherapy in ALCYONE (as of Cycle 11) or daratumumab plus Rd in MAIA. The phase 3 COLUMBA study demonstrated noninferiority of DARA SC to DARA IV. DARA SC reduced administration time, allowing pat…

Analysis of patient's X-ray exposure in hepatic chemosaturation procedures: a single center experience.

BACKGROUND: Hepatic chemosaturation is a technique in which a high dose of the chemotherapeutic agent melphalan is administered directly into the liver while limiting systemic side effects. We reviewed our institutional experience regarding patient's X-ray exposure caused by the procedure. METHODS: Fifty-five procedures, performed between 2016 and 2020 in 18 patients by three interventional radiologists (radiologist), were analyzed regarding the patient's exposure to radiation. Dose-area-product (DAP) and fluoroscopy time (FT) were correlated with the experience of the radiologist and whether…

Cytotoxic Tumour-Selective 1,5-Diaryl-3-Oxo-1,4-Pentadienes Mounted on a Piperidine Ring.

A series of 3,5-bis(benzylidene)-4-piperidones 2a-u were prepared as candidate cytotoxic agents. In general, the compounds are highly toxic … displayed by 2e and 2r. In the case of 2r, its selective toxicity exceeded that of doxorubicin and melphalan. The enones 2k, m, o have the highest SI values towards colon cancer and leukemic cells. Both 2e,r inhibited mitosis and increased the subG1 population (with a transient increase in G2/M phase cells). Slight activation of caspase-3, based on the cle …

Reduction of Opioid Use by Acupuncture in Patients Undergoing Hematopoietic Stem Cell Transplantation: Secondary Analysis of a Randomized, Sham-Controlled Trial.

ObjectiveTo evaluate acupuncture as a nonpharmacologic intervention for pain management in patients undergoing hematopoietic stem cell transplantation (HSCT).MethodsAdult patients with multiple myeloma undergoing high-dose melphalan chemotherapy and autologous peripheral blood HSCT were randomized to receive either true (TA) or sham acupuncture (SA) once daily for five days starting on the day after chemotherapy. Use of pain medications and pain scores were assessed at baseline and at days 5, 15, and 30 after transplantation.ResultsAmong 60 evaluable subjects, the SA group (vs TA) had greater …

Intra-arterial chemotherapy as second-line treatment for advanced retinoblastoma: A 2-year single-center study in China.

PURPOSE: To evaluate the effectiveness and complications of intra-arterial chemotherapy (IAC) for treating advanced refractory retinoblastom … and complications of these patients were reviewed. RESULTS: All of these patients received IAC of melphalan combined with topotecan. The mean follow-up period was 14.2 months after final IAC (ranged from 3 to 28 months). The rate of eye preservation was 41.67% in Group D and 20.83% in Group E of this study. Short-term ocular adverse events included eyelid …

Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.

The management of light chain (AL) amyloidosis has improved in recent years thanks to accurate biomarker-based staging systems and response … ctively. Complete response after up-front treatment and frontline therapy with combined bortezomib, melphalan, and dexamethasone independently prolonged time to second-line therapy. Median survival of relapsing patients was 59 months. Patients who had a "high-risk dFLC progression," which we defined as a difference between involved and uninvolved free light …